Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells. This enables in vivo or ex vivo delivery via a single viral vector. Epic’s lead program, EPI-321, is in IND-enabling studies […]
Still a relatively new technology, CRISPR has been heralded in recent years as having the potential to tackle a range of diseases. And now, it has finally proved its worth. In a world first, the U.S. Food and Drug Administration (FDA) has approved CASGEVY – the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR […]
HIV continues to represent a global health burden, with the World Health Organization (WHO) estimating that, in 2022, there were 39 million people living with the virus. But there is still no effective cure for it. The only option patients have is antiretroviral therapy, which, although it represents a major milestone in HIV treatment and […]
CRISPR-based microbial gene therapy company SNIPR Biome ApS has announced positive interim clinical results from its phase 1 clinical trial with SNIPR001. SNIPR Biome’s SNIPR001 is the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. The work was supported by CARB-X, a global […]